CompletedNot Applicable

Noninvasive Hemodynamics Assessment of Preterms With Successful Medical Closure of PDA

Egypt43 participantsStarted 2023-10-01

Plain-language summary

The aim of our study was to use Electrical Cardiometry EC to monitor hemodynamic alternations during pharmacological closure of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm neonates

Who can participate

Age range24 Hours – 7 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All preterm newborns who were admitted throughout the duration of the research. Exclusion Criteria: * Newborn with congenital heart diseases. * Newborn with acquired heart diseases (viral myocarditis) * Newborn with dysrhythmias * Newborn with symptomatic cardiac dysfunction secondary to extra cardiac diseases * Newborn with significant pulmonary hypertension or systemic hypertension

What they're measuring

Stroke volume (SV)

Timeframe: 6 months

Cardiac output (CO)

Timeframe: 6 months

Systemic vascular resistance (SVR)

Timeframe: 6 months

Total fluid content (TFC)

Timeframe: 6 months

Trial details

NCT IDNCT06606015

SponsorTanta University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-04-01

View on ClinicalTrials.gov More Patent Ductus Arteriosus in Preterm Infants trials